Risk of transformation to AML associated with autoimmune disease
| MDS group . | HR∗ . | 95% CI† . | P interaction‡ . |
|---|---|---|---|
| Low histologic risk | 1.87 | 1.17-2.99 | |
| Intermediate histologic risk | 0.93 | 0.77-1.11 | .009 |
| High histologic risk | 1.11 | 0.87-1.41 |
| MDS group . | HR∗ . | 95% CI† . | P interaction‡ . |
|---|---|---|---|
| Low histologic risk | 1.87 | 1.17-2.99 | |
| Intermediate histologic risk | 0.93 | 0.77-1.11 | .009 |
| High histologic risk | 1.11 | 0.87-1.41 |
Results are adjusted for all factors included in the regression model for leukemic transformation (Table 3).
Results indicate the risk of AML transformation associated with preexisting autoimmune disease (reference group comprises those with absence of preexisting autoimmunity).
Value for the interaction term (interaction between presence or absence of autoimmune disease and histologic risk category).